CLLS
Cellectis S.A.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
4.74
P/S
3.55
EV/EBITDA
-9.25
DCF Value
$-5.31
FCF Yield
-16.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.6%
Operating Margin
-47.6%
Net Margin
-92.9%
ROE
-69.6%
ROA
-20.9%
ROIC
-17.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $10.6M | $-26.3M | $-0.27 |
| FY 2025 | $73.2M | $-67.8M | $-0.68 |
| Q3 2025 | $35.2M | $589.0K | $0.01 |
| Q2 2025 | $16.7M | $-23.7M | $-0.24 |
Analyst Ratings
View AllCompany Info
Sector
Healthcare
Industry
—
Country
FR
Exchange
NASDAQ
Beta
2.71
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.